Search

Your search keyword '"Feld, R."' showing total 729 results

Search Constraints

Start Over You searched for: Author "Feld, R." Remove constraint Author: "Feld, R."
729 results on '"Feld, R."'

Search Results

Catalog

Books, media, physical & digital resources

10. Abstracts

13. Mental health and vitality among Canadian women with physical disabilities

21. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer

22. Search for Charged Higgs Bosons Produced via Vector Boson Fusion and Decaying into a Pair of W and Z Bosons Using pp Collisions at root s=13 TeV

23. Advantages of Electromagnetic Interferometry Applied to Ground-Penetrating Radar: Non-Destructive Inspection and Characterization of the Subsurface Without Transmitting Anything

24. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer

26. Search for leptophobic Z ' bosons decaying into four-lepton final states in proton-proton collisions at root s=8 TeV

27. Search for new physics in the monophoton final state in proton-proton collisions at root s=13 TeV

29. Reply to V. Lorusso et al

30. Advantages of Electromagnetic Interferometry Applied to Ground-Penetrating Radar: Non-Destructive Inspection and Characterization of the Subsurface Without Transmitting Anything

33. A case of recurrent metastatic ameloblastoma and hypercalcaemia successfully treated with carboplatin and paclitaxel: long survival and prolonged stable disease

34. First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced Non Small Cell Lung Cancer. The TORCH randomised trial

42. Cmet Expression and Activity of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): Exploratory Analysis of the Randomized Phase III Torch Trial

43. Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts)

44. Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients

47. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

49. Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial.